Skip to content
  • Home
  • About
  • Resources
    • Podcast
    • News
    • Webinars
    • Virtual Conference 2021
      • SCN2A Phenotypes
      • Loss of function gene mutations in SCN2A
      • Collaboration with families
      • Understanding clinical variability for variants in the same gene
      • Praxis SCN2A Programs: An Update
      • SCN2A Research Registry in Simons Searchlight
      • Genetic Information
      • Support for SCN2A and genetic epilepsy families
  • Research
    • Australian
    • International
    • Currently Enrolling
    • SCN2A Simplified
  • Events
  • Contact
Menu
  • Home
  • About
  • Resources
    • Podcast
    • News
    • Webinars
    • Virtual Conference 2021
      • SCN2A Phenotypes
      • Loss of function gene mutations in SCN2A
      • Collaboration with families
      • Understanding clinical variability for variants in the same gene
      • Praxis SCN2A Programs: An Update
      • SCN2A Research Registry in Simons Searchlight
      • Genetic Information
      • Support for SCN2A and genetic epilepsy families
  • Research
    • Australian
    • International
    • Currently Enrolling
    • SCN2A Simplified
  • Events
  • Contact
Donate
Search
Close

antisense oligonucleotide

Read more about the article Loss of function gene mutations in SCN2A: Implications and opportunities for therapeutic intervention

Loss of function gene mutations in SCN2A: Implications and opportunities for therapeutic intervention

  • Post author:David Cunnington
  • Post published:April 14, 2021
  • Post category:Conference 2021
  • Post comments:0 Comments

Professor Steven Petrou explains how mutations in the SCN2A gene can lead to loss of function, and how treatments could increase function.

Continue ReadingLoss of function gene mutations in SCN2A: Implications and opportunities for therapeutic intervention
Read more about the article Antisense Oligonucleotides (ASOs)

Antisense Oligonucleotides (ASOs)

  • Post author:David Cunnington
  • Post published:December 23, 2019
  • Post category:Podcast
  • Post comments:0 Comments

Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work?

Continue ReadingAntisense Oligonucleotides (ASOs)
Read more about the article Developing Treatment for SCN2A

Developing Treatment for SCN2A

  • Post author:SCN2A Australia
  • Post published:November 23, 2019
  • Post category:Webinar
  • Post comments:0 Comments

Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.

Continue ReadingDeveloping Treatment for SCN2A
Read more about the article Webinar – Working towards SCN2A treatment

Webinar – Working towards SCN2A treatment

  • Post author:David Cunnington
  • Post published:November 21, 2019
  • Post category:
  • Post comments:0 Comments

Speakers: Prof. Steven Petrou, Director of the Florey and RogCon, Chief Scientific Officer, and Dr. Kiran Reddy, CEO of Praxis Precision Medicines. At the 2018 American Epilepsy Society meeting, Prof…

Continue ReadingWebinar – Working towards SCN2A treatment
Read more about the article Developing Treatments for SCN2A

Developing Treatments for SCN2A

  • Post author:SCN2A Australia
  • Post published:November 10, 2019
  • Post category:Podcast
  • Post comments:0 Comments

We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.

Continue ReadingDeveloping Treatments for SCN2A

Newsletter

Email is required Email is not valid
This field is required
Thanks for your subscription.
Failed to subscribe, please contact admin.

Facebook

Twitter

My Tweets
Facebook-f Twitter Instagram Envelope

© All rights reserved. SCN2A Australia  |  Privacy Policy